3
Clinical Trials associated with Allogeneic anti-IL3RA|NKG2D CAR-T (Tianjin First Center Hospital) / SuspendedEarly Phase 1IIT CD123 chimeric antigen receptor T cells (CART) therapy for relapse or refractory Blastic plasmacytoid dendritic cell neoplasm
Start Date19 Mar 2019 |
Sponsor / Collaborator- |
Donor-derived Anti-CD123-CART Cells for relapse AML After Allo-HSCT
Start Date17 Dec 2018 |
Sponsor / Collaborator- |
/ RecruitingNot ApplicableIIT A Clinical Research of CD123-Targeted CAR-T in CD123 positive refractory or relapsed Myeloid leukemia
Start Date13 Aug 2018 |
Sponsor / Collaborator- |
100 Clinical Results associated with Allogeneic anti-IL3RA|NKG2D CAR-T (Tianjin First Center Hospital)
100 Translational Medicine associated with Allogeneic anti-IL3RA|NKG2D CAR-T (Tianjin First Center Hospital)
100 Patents (Medical) associated with Allogeneic anti-IL3RA|NKG2D CAR-T (Tianjin First Center Hospital)
100 Deals associated with Allogeneic anti-IL3RA|NKG2D CAR-T (Tianjin First Center Hospital)